ArticleCancer biomarkers : section A of Disease markers2019
Potential diagnostic and prognostic value of plasma long noncoding RNA LINC00086 and miR-214 expression in gastric cancer.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis.BioMed research international · 2022Pooled it
- Circulating long noncoding RNAs as potential biomarkers for stomach cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2021Pooled it
- Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review.Advances in therapy · 2021Pooled it
- Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics.Clinical epigenetics · 2026Article
- Article
- Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers.Clinical and experimental medicine · 2024Review
- Bibliometric and visualized analysis of global research on microRNAs in gastric cancer: from 2013 to 2023.Frontiers in oncology · 2024Review
- Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.Journal of gastric cancer · 2024Review
- Cell-free Nucleic Acid as Promising Diagnostic Biomarkers for Gastric Cancer: a Systematic Review.Journal of Cancer · 2024Article
- Novel biomarkers for early detection of gastric cancer.World journal of gastroenterology · 2023Review
- Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer.BMC bioinformatics · 2023Article
- Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).Bioengineered · 2021Article
- New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids.Archives of toxicology · 2021Article
- Clinical crosstalk between microRNAs and gastric cancer (Review).International journal of oncology · 2021Review
- Risk Factors and Their Diagnostic Values for Ocular Metastases in Gastric Adenocarcinoma.Cancer management and research · 2021Article
- Article
- Diagnostic and prognostic value of the peripheral natural killer cell levels in gastric cancer.Experimental and therapeutic medicine · 2020Article
- Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance.Molecular cancer · 2020Review
- LncRNA ZEB1-AS1 down-regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasma carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) are common markers which are useful in the diagnosis and prognosis of GC. However, their sensitivity and specificity in GC remain unsatisfactory. Identification of cancer diagnosed-biomarkers would be of great value.
objectiveEvaluate the diagnostic and prognostic value of LINC00086 and miR-214 in GC.
methodsIn this study, we determined the expression of LINC00086 and miR-214 in GC by qRT-PCR. Additionally, we investigated the relationship between various clinicopathological features of GC patients and LINC00086 or miR-214 expression, and evaluated the diagnostic and prognostic value of LINC00086 and miR-214 in GC.
resultsIn this study, we found that plasma LINC00086 expression was significantly lower, whereas plasma miR-214 expression was significantly higher in GC patients than in normal individuals. LINC00086 and miR-214 exhibited high sensitivity and specificity in diagnosing GC. Additionally, GC patients with low LINC00086 or high miR-214 expression were likely to have larger tumors, lymphatic metastasis, larger TNM stage, and higher CEA and CA19-9 levels. Moreover, GC patients with low LINC00086 or high miR-214 expression showed lower survival rates. Lymphatic metastasis, LINC00086, and miR-214 are independent factors affecting patient diagnosis.
conclusionsLINC00086 and miR-214 are potentially diagnostic and prognostic markers for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.